Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia

Running Title

Multi-gene qPCR-based PGx panel for Asians

Authors

Anar Sanjaykumar KOTHARY^{1,*}, Caroline MAHENDRA^{1,*}, Mingchen TAN¹, Eunice Jia Min TAN², Jacelyn PHUA Hong Yi¹, GABRIELLA¹, TAN Xin Hui Jocelyn¹, Jessline Stephanie HARUMAN¹, Chun Kiat LEE², Benedict YAN^{2,3}, Astrid IRWANTO^{1,4,#}

Affiliations

¹Nalagenetics Pte Ltd, Singapore, Singapore

²Department of Laboratory Medicine, National University Health System, Singapore

³Stronghold Diagnostics Lab, Agency for Science, Technology and Research, Singapore

⁴Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore

^{*}equal contribution

[#]corresponding author: astrid@nalagenetics.com

Acknowledgements

We would like to thank Mr. Xie Zhicheng and Mr. Heng Khai Koon at the Genome Institute of Singapore for their assistance with performing the Agena VeriDose® Core and *CYP2D6* CNV Panel studies. We also thank Dr. Tan Zhihao for his feedback on the data analysis approach and manuscript, and PT Nalagenetik Riset Indonesia for their assistance in study recruitment and experimentation performed in Indonesia.

1 Abstract

Background – With up to 70% of adverse drug reactions (ADRs) having high genetic associations, the clinical utility of pharmacogenomics (PGx) has been gaining traction. Nala PGx Core[™] is a multi-gene qPCR-based panel that comprises 18 variants and 2 *CYP2D6* Copy Number markers across 4 pharmacogenes – *CYP2C9*, *CYP2C19*, *CYP2D6* and *SLCO1B1*.

7

8 Objectives – In this study, we validated the performance of Nala PGx Core[™] against benchmark methods, on the
 9 Singaporean and Indonesian populations. Additionally, we examined the allele and diplotype frequencies across 5
 10 major ethnic groups present in these populations namely, Indonesians, Chinese, Malays, Indians and Caucasians.

11

Methods – Human gDNA samples, extracted from the buccal swabs of 246 participants, were tested on Nala PGx Core[™] and two chosen benchmarks, Agena VeriDose[®] Core and *CYP2D6* Copy Number Variation (CNV) Panel, and TaqMan[®] DME Genotyping Assays. Performance was evaluated based on assay robustness, precision and

15 accuracy at the genotype- and diplotype-level.

16

17**Results** – Nala PGx CoreTM demonstrated high genotype- and diplotype-level call rates of >97% and >95%18respectively in *CYP2D6*, and 100% for *CYP2C9*, *CYP2C19* and *SLCO1B1*. A precision rate of 100% was observed19on both intra- and inter-precision studies. Variant-level concordance to the benchmark methods was \geq 96.9% across20all assays, which consequently resulted in a diplotype-level concordance of \geq 94.7% across *CYP2C9*, *CYP2C19* and21*CYP2D6*. Overall, the allele frequencies of *CYP2D6*10* and *CYP2D6*36* were higher in our cohort as compared to22previous records. Notably, *CYP2D6* copy number variation (CNV) analysis demonstrated a *CYP2D6* *10/*3623frequency of 26.5% amongst the Indonesian cohort.

24

Conclusion –Nala PGx Core[™] produced robust and accurate genotyping when compared to other established
 benchmarks. Furthermore, the panel successfully characterized alleles of clinical relevance in the Singaporean and
 Indonesian populations such as *CYP2D6*10* and *CYP2D6*36*, suggesting its potential for adoption in clinical
 workflows regionally.

29

30 Keywords: Pharmacogenomics; *CYP2C9*; *CYP2C19*; *CYP2D6*; *SLCO1B1*; qPCR; adverse drug reactions;
31 Singapore; Indonesia.

- 32
- 33 Abstract count: 290 words, 1764 characters
- 34 Main text count: 4337 words

35 Introduction

Pharmacogenomics (PGx) is a branch of medicine concerned with determining the response of an individual to
therapeutic drugs using genetic and/or genomic information¹. With up to 70% of adverse drug reactions (ADRs)
having high genetic associations², and the sunk cost of trial-and-error prescriptions amounting to USD 30 billion³,
the clinical utility⁴ of PGx appears to be gaining prominence.

40

41 Applications of PGx include the genotyping of Cytochrome P450 (P450) enzymes which are significantly involved 42 in drug metabolism and chemical toxicity⁵. *CYP2C9*, *CYP2C19* and *CYP2D6* display common polymorphisms that 43 produce altered enzyme activity, often resulting in deviant drug metabolism that leads to side effects from drugs 44 metabolized by them⁵.

45

46 Alterations in CYP2C9 can disrupt the metabolism of warfarin, while CYP2C19 is associated with the metabolism of a number of drugs including clopidogrel, omeprazole and phenytoin^{6,7}. The highly polymorphic *CYP2D6* has more 47 48 than 100 variants and is responsible for the metabolism of approximately 25% of all clinically used drugs, including 49 codeine, fluoxetine and amitriptyline⁷. For this reason, pharmaceuticals are particularly cautious in the development of drugs that are known to interact with these three P450s⁵. Additionally, pharmacogenes, such as SLCO1B1, are 50 51 responsible for encoding transporters of simvastatin and other statins into tissues also affect their response upon 52 intake in individuals. Variants of this gene are associated with increased risk of muscle pain (myalgia) and damage, 53 including myopathy and in severe cases rhabdomyolysis⁸. Previous studies suggest the role of specific CYP2C19 54 and SLCO1B1 variants in the bioactivation of drugs such as clopidogrel and atorvastatin in the Singaporean 55 population^{9,10}. The CYP2C19 variant, rs4986893, which is implicated in reduced clopidogrel metabolism, has been 56 observed to be 50 times more prevalent in the Singaporean Chinese population than in Europeans¹⁰. The SLCO1B1 57 variant, rs4149056, which is implicated in statin metabolism, has been observed to occur less frequently in the Singaporean population⁹. Taken together, these cases highlight the need to harness PGx testing to account for 58 59 population differences in the personalization of prescriptions¹¹.

60

61 Current methods on PGx testing for the identification of genetic polymorphisms revolve around variant genotyping 62 that utilize technologies ranging from Next Generation Sequencing (NGS), Microarray, Mass Spectrometry to 63 Quantitative PCR (qPCR)^{1,6,12,13}. Main considerations in the adoption of a platform include its robustness, 64 effectiveness and cost-saving, especially in localities with limited resources. qPCR-based assays satisfy these criteria and are a preferred platform for clinical laboratories¹⁴⁻¹⁹. However, some of the available commercial kits are 65 limited in their ability to test the 4 genes of interest mentioned above in a single panel^{20–25}. Nala PGx Core[™] is a 66 67 qPCR-based multi-gene panel consisting of 20 pharmacogenomic variants that are associated with altered CYP2C9, 68 CYP2C19, CYP2D6 and SLCO1B1 activity in Asian geographies. Our study aims to evaluate the performance of 69 Nala PGx CoreTM in effectively identifying genetic variations that may contribute to PGx-related clinical outcomes 70 in Singapore and Indonesia, with a secondary objective of highlighting the allele and diplotype frequencies in the

71 geographies examined.

72 Methods and Materials

73 Ethics Approval

- 74 Institutional Review Board (IRB) approval was granted by the Parkway Independent Ethics Committee (Singapore)
- vinder IRB Reference Number PIEC/2019/021 and Siloam Hospitals Ethics Review Committee (Jakarta, Indonesia)
- 76 under IRB Reference Number 001/EA/KEPKK/RSMRCCC/V/2019.

77 Study Recruitment

- Patients were recruited on behalf of Nalagenetics Pte. Ltd. with written informed consent forms from recruitment sites in Singapore and Indonesia. A total of 251 samples were evaluated from 5 major ethnic groups to ensure the representation of the major ethnic groups residing in both countries – Chinese, Malays, Indians, Caucasians and Indonesians. Participants identifying as one or more of the following ethnicities were categorized as Indonesians: Ambon, Batak, Betawi, Jawa, Lampung, Manado, Minangkabau, Nusa Tenggara Timur, Palembang, Sulawesi,
- 83 Sunda, Timor Leste, Tolaki and Toraja.
- 84
- 85 Buccal samples were collected using OraCollect (Cat No. DNA OCR-100 from DNA Genotek) and genomic DNA
- 86 (gDNA) extracted using the Monarch Genomic DNA Purification Kit (Cat No. T3010 from NEB). The extraction
- 87 procedure followed manufacturer's instructions with additional dry-spin step at maximum speed for 1 minute after
- the 2nd buffer washing step. The quality and concentration of gDNA extracts were quantified by NanoDrop 2000
- 89 Spectrophotometer (Singapore) and BioDrop-µLITE (Indonesia). Samples that failed to meet the DNA quality
- 90 control criteria (n=5) of A260/280 >1.7 and DNA yield >500ng were excluded from the study. The remaining
- 91 extracted gDNA samples (n=246) were stored at $-20\Box$ for downstream application.

92 Nala PGx CoreTM

- The Nala PGx CoreTM kit from Nalagenetics Pte. Ltd. consists of 20 qPCR-based variant assays across four genes CYP2C9, CYP2C19, CYP2D6 and SLCO1B1. Whilst assays for CYP2C9, CYP2C19 and CYP2D6 have been
- 95 designed to enable the detection of specific star alleles, the *SLCO1B1* assay has been designed to detect the variant
- 96 rs4149056, which is present in three reduced function haplotypes namely, SLCO1B1*5, SLCO1B1*15 and
- 97 SLCO1B1*17. The SLCO1B1 assay is thus, unable to differentiate between each of the three aforementioned
- haplotypes. The variants covered by the kit are outlined in Table 1.
- 99
- 100 Assays were set up on a 96-well plate. Human gDNA was added at a concentration of 2 ng/µL as template for the
- 101 qPCR reaction, which was then performed on the Bio-Rad CFX96 IVD TouchTM Real-Time PCR Detection System
- 102 per the product insert. Run analysis was performed using the application CFX Manager 3.1 or CFX Maestro, and
- 103 exported as raw .csv files. Exported files were uploaded into the companion software, Nala Clinical Decision
- 104 SupportTM (Nala CDSTM) for further analysis of variant genotyping, diplotype determination and phenotype
 - 3

- 105 translation. Genotyping using Nala PGx CoreTM was performed at the Molecular Diagnosis Centre, National
- 106 University Health System, Singapore (NUHS MDC) and PT Nalagenetik Riset Indonesia.

107 Agena VeriDose® Core and CYP2D6 Copy Number Variation (CNV) Panel

- 108 The VeriDose® Core and CYP2D6 Copy Number Variation (CNV) Panel from Agena Bioscience® consists of 68
- 109 variant assays in 20 genes and 5 CYP2D6 CNV assays, accompanied by a reporting software that automatically
- 110 analyzes each variation²⁶. Genotyping using Agena VeriDose Core and *CYP2D6* CNV Panel was performed at the
- 111 Genome Institute of Singapore. Variants evaluated using this platform are listed in Table 1. The Agena VeriDose®
- 112 Panel has been utilized by the United States Centers for Disease Control and Prevention (CDC) as part of their
- 113 Genetic Testing Reference Material (GeT-RM) Coordination Program²⁷.

114 TaqMan® Drug Metabolism Enzyme (DME) Genotyping Assay

115 TaqMan® DME Genotyping Assays were utilized in the evaluation of CYP2D6 rs769258 (TaqMan Assay ID

- 116 AH21B9N) and *CYP2D6* rs267608319 (TaqMan Assay ID C_27102444_F0). Assays were set up on a 384-well
- 117 plate²⁸ with a sample input of human gDNA at 2 $ng/\mu L$. The subsequent PCR reaction was performed on the
- 118 Applied Biosystems ViiATM 7 Real-Time PCR System as per the recommended cycling conditions, at the Genome
- 119 Institute of Singapore. Post-PCR plate read was performed using the companion software, TaqMan® Genotyper[™]
- 120 Software for single nucleotide polymorphisms (SNP) genotyping. Similar to the Agena VeriDose® Panel,
- 121 TaqMan® DME Genotyping Assays were employed in the characterization of DNA samples as part of the CDC
- 122 GeT-RM program²⁷.
- 123

124 Robustness

125 Genotype- and diplotype-level call rates were defined as the percentage of samples that returned a genotype at the

- 126 variant-level or were assigned a distinct diplotype for the gene of interest, respectively. Failed tests were defined as
- 127 samples that did not return a genotype and/or diplotype call for the genes evaluated.

Call Rates,
$$\% = \frac{\text{Total Sample Size-Failed Tests}}{\text{Total Sample Size}} \times 100\%$$

128

129 Precision

Three samples at 3 DNA concentrations were tested across 3 reagent lots on 2 machines. Each test condition was repeated within the same plate for a triplicate. For variant assays that identified SNPs and indels, intra-precision was performed within the same plate, run as triplicates across 47 tests. Inter-precision was assessed from 120 tests performed across plate runs covering the 4 variables – samples, DNA concentration, reagent lots and machines. Concordance rates across precision studies were calculated as the percentage of tests that returned a genotype call concordant to the expected truth for each variant assay. Discordant genotype was defined as instances when the test

136 returned a genotype call that was different from the expected truth.

Concordance Rate,
$$\% = \frac{\text{No. Of Tests Performed} - \text{No. Of Tests With Discordant Genotype}}{\text{No. Of Tests Performed}} \times 100\%$$

137

138 For *CYP2D6* CNV assays, copy number estimates for Intron 2 and Exon 9 of the three samples were derived based

139 on their cycle threshold (Ct) results across plate runs.

$$Copy Number = 2 \times 2^{-\Delta \Delta Ct}$$

$$\Delta\Delta Ct = \left(Ct_{\text{reference gene calibrator}} \cdot Ct_{CYP2D6 \text{ calibrator}}\right) \cdot \left(Ct_{\text{reference gene}} \cdot Ct_{CYP2D6 \text{ sample}}\right)$$

141

142 Testing of the three samples was repeated for a number of plate runs, n (Table 5), and calculated for the average 143 copy number of each sample and their coefficient of variation (CV). The CV for each plate run was calculated by 144 finding the standard deviation (σ_{plate}) between triplicates within the same plate run, and divided by the triplicate 145 mean (μ_{plate}). The average of the individual CVs was reported as the intra-precision CV. For inter-precision CV, 146 standard deviation population ($\sigma_{plate means}$) was divided by the mean population, i.e. average of means.

Intra- CV,% =
$$\frac{\sum_{n} \frac{\sigma_{plate}}{\mu_{plate}}}{n} \times 100\%$$

147

Inter- CV,% =
$$\frac{\sigma_{\text{plate means}}}{\sum_{n} \mu_{\text{plate}} / n} \times 100\%$$

148 Accuracy

- 149 Variant-level Concordance
- 150 The accuracy of Nala PGx CoreTM in genotyping at a variant-level was evaluated by comparing calls produced by
- 151 Nala PGx CoreTM assay against benchmark methods as listed in Table 1. Samples that successfully produced
- 152 genotype calls for all variants tested on Nala PGx CoreTM and its benchmarks were considered for the evaluation (n
- 153 = 225). Samples that failed to produce a genotype call on one or more of the platforms were excluded from the
- 154 concordance calculation (n = 21, Supplementary Table 8). Discordant calls were defined as instances in which Nala
- 155 PGx CoreTM provided a genotype call that was different from that of a call made by the corresponding benchmark.
- 156 Percentage concordance to the benchmark was calculated per variant as follows –

Concordance To Benchmark Per Variant, $\% = \frac{\text{Total Sample Size - Discordant Calls By Nala PGx Core^{TM}}}{\text{Total Sample Size}} \times 100\%$

157 Diplotype-level Concordance

- 158 The accuracy of Nala PGx Core[™] in assigning a diplotype call for CYP2C9, CYP2C19, and CYP2D6, was
- 159 evaluated by comparing calls against the Agena VeriDose® Core and CYP2D6 CNV Panel. Samples that met the
- 160 following criteria were included in the sample size of each gene:
- 161 1. Successful genotype-level calls on the relevant platforms for all variants covered by the gene of interest
- Successful assignment of a diplotype for the gene of interest on both Nala PGx Core[™], and Agena
 VeriDose® Core and *CYP2D6* CNV Panel
- 164 Discordant calls were defined as instances in which Nala PGx CoreTM assigned a diplotype that differed from the
- 165 call made by the Agena VeriDose® Core and CYP2D6 CNV Panel.

$$Concordance, \% = \frac{\text{Total Sample Size - Discordant Calls By Nala PGx Core^{TM}}}{\text{Total Sample Size}} \times 100\%$$

166 Frequencies By Ethnicity

167 Ethnicities were obtained based on participant self-identification across both the population cohorts as part of the 168 recruitment questionnaire. Participants that did not report an ethnic group in the recruitment form were excluded

- 169 from the frequency analysis. The following were further excluded from the frequency analysis:
- 170 1. Samples in which participants did not report an ethnic group on the recruitment form (n=5)
- 171 2. Samples with one or more variant level failures across the 4 genes evaluated in Table 1 (n=18)
- Samples with one or more diplotype-level failures ("No Call") across *CYP2C9*, *CYP2C19*, and *CYP2D6* on
 Nala PGx Core[™] and the Agena VeriDose[®] Core and *CYP2D6* CNV Panel (n=14)
- 4. Samples with discordant diplotype calls for the gene of interest (n=variable, Supplementary Table 6)
- 175
- 176 The remaining samples were included in the allele-level frequency analysis of CYP2C9 (n=206), CYP2C19 (n=201),
- 177 CYP2D6 (n=195) and SLCO1B1 (n=203), as well as in the diplotype-level frequency analysis of CYP2C9 (n=206),
- 178 CYP2C19 (n=201) and CYP2D6 (n=195). Allele and diplotype frequency values were derived using the following
- 179 formulae^{29,30}, for both the overall study cohort as well as for each ethnic group.

Frequency Of Allele 'V' In A Given Dopulation -	Total Copies Of Allele 'X'		
riequency of Allele X in A Olven Population –	Total Copies Of All Alleles For The Gene Of Interest		

180

 $Frequency Of Diplotype 'X' In A Given Population = \frac{Total Instances Of Diplotype 'X'}{Total Number Of Individuals In The Population}$

181 **Results**

182 Robustness

We first sought to evaluate the observed genotype- and diplotype-level call rates of the platforms evaluated in this study. 246 samples underwent variant genotyping and diplotype determination, across the four genes evaluated on the genotyping platforms (Tables 2, 3). The genotype-level call rates for Nala PGx CoreTM were at 100% for *CYP2C9, CYP2C19* and *SLCO1B1*, and the diplotype-level call rates were at 100% for *CYP2C9* and *CYP2C19*. The benchmark platform, Agena VeriDose[®] Core Panel, demonstrated call rates of >98% at the genotype-level and

- 188 >97% at the diplotype-level.
- 189

190 Most variants in *CYP2D6*, except for seven, achieved 100% call rates on Nala PGx CoreTM, while the corresponding

191 call rates of the benchmark platforms were observed to be between 95.9 – 99.2% on Agena VeriDose® Core and

192 CYP2D6 CNV Panel, and 100% on TaqMan® DME Genotyping Assays. Out of the seven aforementioned variants,

193 Nala PGx CoreTM demonstrated higher call rates than the benchmark for the genotyping of rs1065852, Intron 2 and

194 Exon 9 variants. For rs3892097, rs769258, rs5030865, and rs267608319, the accompanying benchmarks

195 demonstrated higher call rates. At the diplotype-level, Nala PGx CoreTM demonstrated a CYP2D6 call rate of 95.9%

196 as compared to the benchmark, which was observed to be at 90.7% (Table 3).

197 Precision

198 A precision study was conducted to assess the consistency of Nala PGx CoreTM for samples tested under the same 199 conditions (intra-precision) and under different conditions (inter-precision). Both study resulted in 100% 200 concordance for all assays across replicates, demonstrating consistent genotyping results across a range of DNA 201 concentration, reagent lots and machine variations (Table 4). Precision of CYP2D6 CNV assay was reported as the 202 average copy number obtained for Intron 2 and Exon 9 of three samples, and their CV calculated across the test 203 conditions (Table 5). The intra- CV ranged from 3-6% while inter- CV between 5-13%, demonstrating high 204 precision of the assays across variables, where acceptable ranges were intra- CV below 10% and inter- CV below 205 15%³¹.

206

207 Accuracy

208 Variant-level Concordance

To assess the accuracy of the panel, 18 SNPs and 2 *CYP2D6* Copy Number assays were genotyped on the panel, Nala PGx CoreTM, against benchmark methods as listed in Table 1. The 225 sample cohort consisted of DNA samples isolated from buccal swabs that had successfully produced genotype calls for all variants tested on Nala PGx CoreTM and its benchmarks. The sample size per genotype displayed in Table 6 refers to the genotype calls made by the benchmark.

214

11 variants (*CYP2C9* rs1799853, rs1057910; *CYP2C19* rs12248560; *CYP2D6* rs5030655, rs3892097, rs35742686, rs28371725, rs769258, rs5030656, rs59421388, rs267608319) were genotyped against Agena VeriDose® Core with a resulting concordance rate of 100% (N = 225 samples). Discordance was observed for *CYP2C19* rs4244285 (n=7), *CYP2C19* rs4986893 (n=3), *CYP2D6* rs1065852 (n=1), *CYP2D6* rs16947 (n=7), *CYP2D6* rs1135840 (n=5), *CYP2D6* rs5030865 (n=1) and *SLCO1B1* rs4149056 (n=6), with a mismatch rate of 0.44% to 3.1% for the affected assays. Overall, Nala PGx CoreTM demonstrated >96% concordance to the benchmark, Agena VeriDose® Core, for the 16 variants across 225 samples (Table 6).

222

Variants not present on Agena VeriDose® Core, *CYP2D6* rs769258 and *CYP2D6* rs267608319, were genotyped using TaqMan® DME Genotyping Assays. Nala PGx CoreTM demonstrated 100% concordance (N = 225) to the benchmark for both SNPs.

226

For the *CYP2D6* Intron 2 and Exon 9 Copy Number assays, concordance was observed to be at 99.6% and 98.7% respectively, against the Agena *CYP2D6* CNV Panel. Discordant calls were observed in samples with an Intron 2 copy number greater than 3 (n=1), and for samples with an Exon 9 copy number of one (n=1) and two (n=2). The sample size per copy number displayed in Table 7 refers to the copy number calls made by the benchmark.

231

A summary of the concordance percentage as well as the distribution of genotypes of each variant are displayed in
 Table 6. Similarly, the distribution of *CYP2D6* Intron 2 and Exon 9 copy numbers are displayed in Table 7.

234

235 Diplotype-level Concordance

Following successful genotyping at the variant level, we investigated the accuracy of Nala PGx CoreTM in assigning a diplotype call for *CYP2C9*, *CYP2C19* and *CYP2D6*, with reference to the Agena VeriDose® Core and *CYP2D6* CNV Panel. Table 8 displays the percentage concordance after the further exclusion of samples that demonstrated diplotype mismatches arising from technological differences, where technological differences refer to the varying allele coverage of each platform (Supplementary Table 7). These differences were derived from the variant lists of both Nala PGx CoreTM (Table 1) and its benchmark, the Agena VeriDose® Core and *CYP2D6* CNV Panel²⁶.

242

247

Overall, a percentage agreement of 100% for *CYP2C9* (n=213), 96.4% for *CYPC219* (n=223) and 94.7% for *CYP2D6* (n=209) was observed between Nala PGx CoreTM and the benchmark. Discordance was observed at n=1 for all diplotypes listed in Table 8 except for the following with more than one discordant calls: *CYP2C19* *2/*2 (n=4), and *CYP2D6* *4/*36 (n=2).

248 Frequencies By Ethnicity

249 For samples that were concordant on Nala PGx CoreTM and the benchmark platforms, we were able to observe the

allele frequencies amongst the populations residing in Singapore and Indonesia (Table 9). From the combination of

- 251 alleles present in individual's chromosome, we were able to observe both the diplotype and corresponding
- 252 phenotype frequencies amongst our study population (Table 10).

For *CYP2C9*, *3 allele was the most common amongst Chinese and Malay, and *2 allele amongst Caucasian, which is in line with PharmGKB's reported distribution for the East Asian and European populations respectively. Our study also reported *3 allele as the more common variant in Indian population than *2, as opposed to PharmGKB's frequency. These allele frequencies translated to *1/*3 as a common diplotype observed in Chinese, Malay and Indians, and *1/*2 in Caucasians.

259

For *CYP2C19*, we observed highest frequency of *CYP2C19*2* amongst Chinese, Malay and Indonesian which were categorized as East Asian populations. This resulted into high frequency of *1/*2 heterozygous depicted as a common diplotype amongst the population. The alleles *2 and *17 were observed as the common variants at equal proportions of 0.229 in Indians and 0.138 in Caucasians. *CYP2C19*3* was a common minor allele least observed amongst Indians and Caucasians, 0 and 0.017 respectively. As a result, *1/*2 and *1/*17 were common diplotypes observed in Indian and Caucasian populations, and *2/*17 only seen in Indians.

266

267 Common polymorphisms of CYP2D6 in our population were seen in *10 and *36 alleles, at almost two-fold higher 268 frequencies in Chinese, Malay and Indonesian than Indians. We noticed high frequencies of *36 in our East Asian 269 population. Additionally, two functional copies of *36 allele were present in 1.4% of Chinese population who 270 participated in our study (Figure 1). These alleles resulted in high frequency of *10/*36 as common diplotype 271 amongst Chinese, Malay and Indonesian population. Our Indian population observed equal distribution of alleles *2, 272 *10 and *36, although PharmGKB reported only *2 as the highest frequency in South Asians. The corresponding 273 common diplotypes observed in Indians were of equal proportions in $\frac{1}{2}$, $\frac{1}{36}$ and $\frac{1}{10}$ ranging from 0.12 to 274 0.16. The alleles *2 and *4 were most common amongst Caucasians as reported by PharmGKB in Europeans, 275 resulting in common diplotypes of *1/*2 and *1/*4 in the population.

276

For *SLCO1B1*, the frequencies of rs4149056 across all ethnicities were consistent with values reported in gnomAD, with the variant being most common amongst Caucasians (0.167) and least amongst Indians (0.040). The frequency amongst East Asians (0.125, gnomAD), as denoted by the Chinese and Indonesian ethnic groups in this study, ranged between 0.074 and 0.125 respectively.

281

282 Discussion

In this study, we evaluated the performance of Nala PGx CoreTM, a qPCR-based panel that evaluates 18 variants and 2*CYP2D6* Copy Number markers across 4 pharmacogenes with established relevance across major ethnic groups in Singapore and Indonesia population. Nala PGx CoreTM comes coupled with a reporting software that supports variant detection, diplotype assignment, diplotype-to-phenotype translation and the generation of reports containing clinical recommendations for each phenotype. The panel demonstrated high genotype-level call rates of >97% for *CYP2D6*, and 100% for *CYP2C9*, *CYP2C19* AND *SLCO1B1*. Similarly, high diplotype-level call rates were observed at >95% for *CYP2D6*, and 100% for *CYP2C9* and *CYP2C19*. A precision of 100% was observed under the

²⁵³

same conditions (intra) and across different conditions (inter). In comparison to other established platforms serving as benchmarks during the study, Nala PGx CoreTM had \geq 96.9% concordance rate for all variant level assays, which consequently resulted in \geq 94.7% concordance at a diplotype level across *CYP2C9*, *CYP2C19* and *CYP2D6*.

293

294 Failures to produce a variant genotype call could be attributed to several reasons. Firstly, failures could potentially 295 stem from the quality of gDNA, despite the DNA quality checks (QC) performed prior to accepting a sample for 296 testing. Further QC that involves specific quantification of double-stranded non-fragmented DNA and traces of other 297 interfering materials like RNA, carryover carbohydrate, residual phenol, guanidine or other reagents could enhance 298 the call rate³². Regardless, the overall higher variant call rates on Nala PGx CoreTM panel demonstrate high tolerance 299 of interfering substances, therefore alluding to the high robustness of the assay. Often, failures at variant genotyping 300 subsequently contribute to failures at determining diplotype, since an incomplete variant panel cannot translate into 301 a diplotype. Failures at diplotype calling could also arise from a combination of variants that do not map onto a 302 distinct diplotype, per the reference database, potentially indicating a novel combination.

303

We further sought to evaluate the allele frequency distribution in the study cohort across the 5 major ethnic groups observed (Indonesian, Chinese, Malay, Indian and Caucasian). The data presented was limited strictly to the geographical boundaries of Singapore and Indonesia, which could account for the difference in allele frequencies observed in comparison to PharmGKB, which is representative of a more expansive and global cohort³³. Whilst dissimilar to database figures, our study demonstrated the distributions for the following to be concordant with previous studies^{7,34,35}, suggesting a niche in the PGx landscape of Singapore and Indonesia –

- 310 1. *CYP2C9*3* allele as the more common variant within Indians than $CYP2C9*2^7$
- 311 2. A *SLCO1B1* rs4149056 frequency of 12.5% amongst Indonesians³⁴
- 312 3. High frequencies of the *CYP2D6*10* amongst Indonesians³⁴
- 313 4. High frequencies of the CYP2D6*36 allele as seen in the Indonesian, Chinese and Malay ethnicities³⁵
- 5. Two functional copies of *CYP2D6* within our Chinese population³⁵

Due to the lack of *CYP2D6* copy number references³⁴, it is our understanding that the frequency of *CYP2D6*36* in Indonesia may not be well-represented. Our study revealed that the prevalence of *CYP2D6*36* to be approximately seventeen times higher amongst Indonesians as compared to the corresponding East Asian allele frequency on PharmGKB³⁶. Furthermore, our study provides insight on the frequency of the *CYP2D6* *10/*36 diplotype in the archipelago, which may help inform the adoption of population-specific PGx workflows in the region. Taken together, the data presents a case for extending tailored PGx testing across the 4 pharmacogenes studied, *CYP2C9*, *CYP2C19*, *CYP2D6* and *SLCO1B1*, in South East Asia.

322 Limitations

323 The single largest reason for the diplotype-level discordance observed between Nala PGx CoreTM and the Agena

324 VeriDose® Core and CYP2D6 CNV Panel appears to be a difference in the technological offerings and hence, allele

325 coverage of each panel. From Supplementary Table 7, out of the 28 instances of discordance observed, 9 instances

327

The variants *CYP2C9*12*, *CYP2C9*13*, *CYP2C19*4A*, *CYP2C19*6* and *CYP2D6*13* were covered by Agena VeriDose® Core but not by Nala PGx CoreTM. Due to lack of coverage for these alleles, the genotypes identified by Nala PGx CoreTM were inconsistent with the calls produced by Agena VeriDose® Core. It is important to note that Nala PGx CoreTM was curated specifically to include alleles that were relevant to Asian and European populations, with a Minor Allele Frequency (MAF) >1% based on PharmGKB database for East Asians, South Asians and Europeans³⁶. Similarly, *CYP2D6*35*, an allele present in 5.5% of Europeans and 1.2% of South Asians, was

- identified by Nala PGx Core[™] but not by Agena VeriDose[®] Core. The technological differences and subsequent
 inconsistencies in reporting suggest the need for further review from a product development standpoint.
- 336

For the highly polymorphic *CYP2D6* gene, Nala PGx CoreTM was designed to only cover the variant alleles listed in Table 1, that could lead to overestimation of *1 allele in our population. This means star alleles that may be present in the population were identified as normal genotype, which could result in overestimation of *1 allele in our population as compared to the PharmGKB's reported frequency (Supplementary Table 4).

341

The study also relied on self-reported ethnicity, which may have contributed to racial bias in summarizing the observed allele and diplotype frequencies per ethnic group. Future studies may consider screening the ethnicities of participants as well as their next-of-kin, up to two generations prior¹⁰, to improve classification accuracy.

345

Finally, the study cohort consisted of 246 individuals, with each ethnic group consisting of approximately 24 to 75 individuals for the frequency analysis. Larger scale studies may be conducted to ensure that the trends observed as part of this study may be generalized across the populations examined.

part of this study may be generalized across the populations examined.

349 **Future Work**

350 Further investigation is required for the remaining samples that had discrepant genotypes across platforms. Nala 351 PGx CoreTM was designed as a qPCR platform and genotyping was accompanied by Nala CDSTM that utilized 352 quantitative thresholds. There could be cases of samples displaying borderline or ambiguous qPCR amplification 353 curves and Ct-values, which could be misinterpreted by these thresholds. The benchmark platforms, Agena 354 VeriDose® Core and CYP2D6 CNV Panel and TaqMan® DME Genotyping Assays, were also analyzed by their 355 accompanying software packages. Such ambiguous cases on either platform could lead to instances of discordance 356 and sequencing of the region of interest may be required to ascertain the truth. For gene variants caused by SNPs and indels, the qPCR amplified product can be submitted for genome sequencing¹³. In the investigation of copy 357 358 number variants, a two-step approach can be adopted³⁷. Firstly, CNV calls observed in this study may be checked 359 against an alternative benchmark such as digital droplet PCR (ddPCR)³⁸. Secondly, where discordance in CNV 360 calling persists, methods such as XL-PCR can be adopted to identify the presence of CYP2D6/CYP2D7 hybrid

³²⁶ were attributed to this cause (32.1%). This included two alleles each in *CYP2C9*, *CYP2C19* and *CYP2D6*.

- 361 states, with submitting samples for whole-genome sequencing³⁷ being an option. Investigation of copy number
- 362 variants may require amplification of region spanning across the gene of interest.

363 **Conflict of Interest**

- A.S.K., M.T., J.P., J.T., C.M., G., J.S.H., and A.I. are employees of Nalagenetics Pte Ltd. A.I. has financial holdings
- 365 in Nalagenetics Pte Ltd. Nalagenetics Pte Ltd and PT Nalagenetik Riset Indonesia are the license holders of Nala
- 366 PGx CoreTM.

367 Funding

- 368 All expenses for this study were funded by Nalagenetics Pte Ltd and PT Nalagenetik Riset Indonesia.
- 369

370 Data Availability Statement

- 371 The data that supports the findings of this study are available as supplementary materials. Any additional data is
- available from the corresponding author upon reasonable request.

373 References

- Berm EJJ, Looff M de, Wilffert B, et al. Economic Evaluations of Pharmacogenetic and Pharmacogenomic
 Screening Tests: A Systematic Review. Second Update of the Literature. Bruns H, ed. *PLoS One*.
 2016;11(1):e0146262. doi:10.1371/journal.pone.0146262
- Chan SL, Ang X, Sani LL, et al. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. *Br J Clin Pharmacol*. 2016;82(6):1636-1646.
 doi:10.1111/bcp.13081
- 380
 3. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. *J Pharmacol Pharmacother*. 2013;4(SUPPL.1). doi:10.4103/0976-500X.120957
- Zhu Y, Lopes GS, Bielinski SJ, et al. Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events. *Mayo Clin Proc Innov Qual Outcomes*. 2021;5(1):35-45. doi:10.1016/j.mayocpiqo.2020.08.009
- 3855.Furge LL, Guengerich FP. Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An
introduction. *Biochem Mol Biol Educ*. 2006;34(2):66-74. doi:10.1002/bmb.2006.49403402066
- Malsagova KA, Butkova T V, Kopylov AT, et al. Pharmacogenetic Testing: A Tool for Personalized Drug
 Therapy Optimization. *Pharmaceutics*. 2020;12(12):1-23. doi:10.3390/pharmaceutics12121240
- 389
 7. Ling Goh L, Wei Lim C, Cheng Sim W, Xian Toh L, Pang Leong K. Analysis of Genetic Variation in 390
 CYP450 Genes for Clinical Implementation. Published online 2017. doi:10.1371/journal.pone.0169233
- Kisor DF, Hoefer C, Decker BS. Pharmacogenomics and precision medicine. In: *Clinical Pharmacy Education, Practice and Research: Clinical Pharmacy, Drug Information, Pharmacovigilance, Pharmacoeconomics and Clinical Research.* Elsevier; 2018:437-451. doi:10.1016/B978-0-12-814276 9.00031-3
- 395 9. Ooi BNS, Raechell, Ying AF, et al. Robust Performance of Potentially Functional SNPs in Machine
 396 Learning Models for the Prediction of Atorvastatin-Induced Myalgia. *Front Pharmacol*. 2021;12:605764.
 397 doi:10.3389/fphar.2021.605764
- Brunham LR, Chan SL, Li R, et al. Pharmacogenomic diversity in Singaporean populations and Europeans.
 Pharmacogenomics J. 2014;14(6):555-563. doi:10.1038/tpj.2014.22
- 400 11. Bachtiar M, Ooi BNS, Wang J, et al. Towards precision medicine: interrogating the human genome to
 401 identify drug pathways associated with potentially functional, population-differentiated polymorphisms.
 402 Pharmacogenomics J. 2019;19(6):516-527. doi:10.1038/s41397-019-0096-y

403	12.	Perkel J. SNP genotyping: Six technologies that keyed a revolution. <i>Nat Methods</i> . 2008;5(5):447-453.
404 405	13.	doi:10.1038/nmeth0508-447 Yang W, Wu G, Broeckel U, et al. Comparison of genome sequencing and clinical genotyping for
406		pharmacogenes. Clin Pharmacol Ther. 2016;100(4):380-388. doi:10.1002/cpt.411
407	14.	S.A. Deepak, K.R. Kottapalli, R. Rakwal, et al. Real-Time PCR: Revolutionizing Detection and Expression
408		Analysis of Genes. <i>Curr Genomics</i> . 2007;8(4):234-251. doi:10.2174/138920207781386960
409	15.	Pratt VM, Zehnbauer B, Wilson JA, et al. Characterization of 107 genomic DNA reference materials for
410		CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: A GeT-RM and association for molecular
411		pathology collaborative project. J Mol Diagnostics. 2010;12(6):835-846. doi:10.2353/jmoldx.2010.100090
412	16.	Pratt VM, Everts RE, Aggarwal P, et al. Characterization of 137 Genomic DNA Reference Materials for 28
415		Pharmacogenetic Genes: A Ge1-RM Collaborative Project. J Mol Diagnostics. 2016;18(1):109-123.
414	17	doi:10.1010/J.JMoidx.2015.08.005
415	17.	Syvanen AC. Accessing genetic variation: Genotyping single nucleotide polymorphisms. <i>Nat Rev Genet</i> .
410	10	2001;2(12):950-942. doi:10.1056/53105353 Suo W. Shi Y. Yu S. Li Y. Lin V. Towards low cost multiplex clinical constraints: 4 fluorescent
417	10.	Kompetitive Allele Specific PCP and its application on pharmacogenetics. Kalendar P. ed. PLoS One
410 //10		2020:15(3):e0230445. doi:10.1371/journal.pone.0230445
$\frac{11}{420}$	10	Shen GO Abdullah KG Wang OK. The TagMan method for SNP genotyping. Methods Mol Riol
$\frac{+20}{421}$	19.	2009:578:293-306 doi:10.1007/978-1-60327-411-1.19
$\frac{121}{422}$	20	Davis BH, DeFrank G, Limdi NA, Harada S, Validation of the Spartan RX CYP2C19 Genotyping Assay
423	20.	Utilizing Blood Samples. Clin Transl Sci. 2020:13(2):260-264. doi:10.1111/cts.12714
424	21	Zhou Y Armstead AR Coshatt GM Limdi NA Harada S Comparison of two point-of-care cyp2c19
425	21.	genotyping assays for genotype-guided antiplatelet therapy. Ann Clin Lab Sci. 2017:47(6):738-743.
426	22.	Bergmeijer TO, Vos GJ, Claassens DM, et al. Feasibility and implementation of CYP2C19 genotyping in
427		patients using antiplatelet therapy. <i>Pharmacogenomics</i> . 2018;19(7):621-628. doi:10.2217/pgs-2018-0013
428	23.	Chae H, Kim M, Koh Y-S, et al. Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping
429		Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. <i>Biomed Res Int.</i> 2013;2013:1-5.
430		doi:10.1155/2013/154073
431	24.	Lee CC, McMillin GA, Babic N, Melis R, Yeo K-TJ. Evaluation of a CYP2C19 genotype panel on the
432		GenMark eSensor® platform and the comparison to the Autogenomics Infiniti TM and Luminex CYP2C19
433		panels. Clin Chim Acta. 2011;412(11-12):1133-1137. doi:10.1016/j.cca.2011.03.001
434	25.	Vanwong N, Ngamsamut N, Hongkaew Y, et al. Detection of CYP2D6 polymorphism using Luminex
435		xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone
436		levels. Drug Metab Pharmacokinet. 2016;31(2):156-162. doi:10.1016/j.dmpk.2016.01.005
437	26.	Lois A, Everts RE, Nakorchevsky A, et al. The VeriDose Core Panel: Strong Performance When Analyzing
438		Challenging Pharmacogenetic Samples. Accessed April 2, 2021. https://agenabio.com/wp-
439		content/uploads/2020/06/Agena-Conference-Poster-Veridose-Core-V3-G020.pdf
440	27.	Gaedigk A, Turner A, Everts RE, et al. Characterization of Reference Materials for Genetic Testing of
441	•	CYP2D6 Alleles. J Mol Diagnostics. 2019;21(6):1034-1052. doi:10.1016/j.jmoldx.2019.06.007
442	28.	Technologies L. TaqMan ® SNP Genotyping Assays TaqMan ® Predesigned SNP Genotyping Assays,
443		TaqMan ® Custom SNP Genotyping Assays, and TaqMan ® Drug Metabolism Enzyme Genotyping Assays.;
444	20	2014. Demulation Constinue and the Handy Weinham Dringinle, Accessed May 2, 2021
445	29.	https://www.es.emu.edu/.constics/wite/instructions/instructions.DCE.pdf
440	20	Allele frequency. A consect May 2, 2021. https://www.neture.com/scitchle/definition/allele frequency. 200/
447	50. 21	Colculating Inter, and Intro Assay Coefficients of Variability. Accessed May 1, 2021
440	51.	https://salimetrics.com/calculating.inter.and.intra.assay.coefficients.of.variability/
450	37	Matlock B. Assessment of Nucleic Acid Purity Tech Bull NanoDron Spectronhotomators. Published online
451	52.	2015.1.2
452	33	Huddart R Fohner AF Whirl Carrillo M et al Standardized Biogeographic Grouping System for
453	55.	Annotating Populations in Pharmacogenetic Research <i>Clin Pharmacol Ther</i> 2019:105(5):1256-1262
454		doi:10.1002/cpt.1322
455	34.	Runcharoen C, Fukunaga K, Sensorn I. et al. Prevalence of pharmacogenomic variants in 100
456		pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian
457		Pharmacogenomics Research Network (SEAPharm). Hum Genome Var. 2021;8(1):7. doi:10.1038/s41439-
458		021-00135-z

- 459 35. Chan W, Li MS, Sundaram SK, Tomlinson B, Cheung PY, Tzang CH. CYP2D6 allele frequencies, copy number variants, and tandems in the population of Hong Kong. *J Clin Lab Anal.* 2019;33(1).
 461 doi:10.1002/jcla.22634
- 462 36. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics Knowledge for Personalized Medicine. *Clin Pharmacol Ther*. 2012;92(4):414-417. doi:10.1038/clpt.2012.96
- 464 37. Pös O, Radvanszky J, Styk J, et al. Copy Number Variation: Methods and Clinical Applications. *Appl Sci.* 2021;11(2):819. doi:10.3390/app11020819
- 466 38. Gross AM, Ajay SS, Rajan V, et al. Copy-number variants in clinical genome sequencing: deployment and interpretation for rare and undiagnosed disease. *Genet Med.* 2019;21(5):1121-1130. doi:10.1038/s41436-018-0295-y
 469

470

Tables

Table 1 Genes and variants evaluated

						Genotyping Methods Utilized		ilized	
Gene	Star Allele	Variant	Nucleotide Changes	Effect On Protein	Allele Clinical Function Status	Nala PGx Core tm	Agena VeriDose® Core and <i>CYP2D6</i> CNV Panel	TaqMan® DME Genotyping Assays	
CVD2 CO	*2	rs1799853	3608C>T	R144C	Decreased	Bi-allelic Assay	VeriDose Core		
СҮР2С9	*3	rs1057910	42614A>C	I359L	None	Bi-allelic Assay	VeriDose Core		
	*2	rs4244285	19154G>A	Splicing Defect	None	Bi-allelic Assay	VeriDose Core		
CYP2C19	*3	rs4986893	17948G>A	W212X	None	Bi-allelic Assay	VeriDose Core		
	*17	rs12248560	-806C>T	5' Region	Increased	Bi-allelic Assay	VeriDose Core		
CYP2D6	*2	rs1135840	4181G>C	S486T	Normal	Bi-allelic Assay	VeriDose Core		
	*2	rs16947	2851C>T	R296C	Normal	Bi-allelic Assay	VeriDose Core		
	*3	rs35742686	2550delA	Frameshift	None	Bi-allelic Assay	VeriDose Core		
	*4	rs3892097, rs1065852	1847G>A, 100C>T	Splicing Defect, P34S	None	Bi-allelic Assay	VeriDose Core	lore	
	*5	N/A	N/A	Gene Deletion	None	CNV Assay (Intron 2)	CYP2D6 CNV		
	*6	rs5030655	1708delT	Frameshift	None	Bi-allelic Assay	VeriDose Core		
	*8	rs5030865	1759G>T	G169X	None	Tri-allelic Assay	VeriDose Core		
	*9	rs5030656	2616delAAG	K281del	Decreased	Bi-allelic Assay	VeriDose Core		
	*10	rs3892097, rs1065852	1847G>A, 100C>T	Splicing Defect, P34S	Decreased	Bi-allelic Assay	VeriDose Core		
	*14	rs5030865	1759G>A	G169R	Decreased	Tri-allelic Assay	VeriDose Core		
	*21	rs72549352	2580_2581ins C	Frameshift	None	Bi-allelic Assay	VeriDose Core		
	*29	rs59421388	3184G>A	V338M	Decreased	Bi-allelic Assay	VeriDose Core		
	*31	rs267608319	4043G>A	R440H	None	Bi-allelic Assay	NA	AH21B9N	
	*35	rs769258	31G>A	V11M	Normal	Bi-allelic Assay	NA	C27102444_F0	
	*36	N/A	Recombinatio n at Exon 9	CYP2D6-2D7 Hybrid	None	CNV Assay (Exon 9)	CYP2D6 CNV		
	*41	rs28371725	2989G>A	Splicing Defect	Decreased	Bi-allelic Assay	VeriDose Core		
SLCO1B1	\mathbf{NA}^{\dagger}	rs4149056	g.52422T>C	V174A	Decreased	Bi-allelic Assay	VeriDose Core		

[†]Nala PGx CoreTM detects the variant, rs4149056, which is associated with decreased enzymatic activity and is present in three known *SLCO1B1* haplotypes namely, *SLCO1B1*5*, *SLCO1B1*15* and *SLCO1B1*17*.

Table 2 Observed genotype-level call rates per variant per gene per platform

		Variant Call Rate, % (n=246)				
Gene	Variant	Nala PGx Core TM	Agena VeriDose® Core and CYP2D6 CNV Panel	TaqMan® DME Genotyping Assays		
CYP2C9	rs1799853	100.0	99.2	NA		
	rs1057910	100.0	99.6	NA		
CYP2C19	rs4244285	100.0	99.6	NA		
	rs4986893	100.0	99.6	NA		
	rs12248560	100.0	98.8	NA		
CYP2D6	rs1065852	98.4	95.9	NA		
	rs5030655	100.0	99.2	NA		
	rs3892097	98.8	99.2	NA		
	rs35742686	100.0	98.8	NA		
	rs16947	100.0	99.6	NA		
	rs28371725	100.0	99.2	NA		
	rs1135840	100.0	99.6	NA		
	rs769258	98.8	NA	100.0		
	rs5030865	97.2	99.2	NA		
	rs5030656	100.0	99.6	NA		
	rs59421388	100.0	99.2	NA		
	rs267608319	99.6	NA	100.0		
	CNV Assay (Intron 2)	99.6	99.2	NA		
	CNV Assay (Exon 9)	99.6	99.2	NA		
SLCO1B1	rs4149056	100.0	99.2	NA		

Table 3 Observed diplotype-level call rates per gene per platform

	Diplotype Call Rate, % (n=246)				
Gene	Nala PGx Core TM	Agena VeriDose® Core and CYP2D6 CNV Panel			
СҮР2С9	100.0	97.2			
CYP2C19	100.0	98.8			
CYP2D6	95.9	90.7			

Table 4 Intra-precision and inter-precision concordance rates

		Concordance rate, %		
		Intra-precision	Inter-precision	
Gene	Variant	(47 tests in triplicate)	(120 tests across 4 variables)	
CVD2C0	rs1799853	100%	100%	
CIP2C9	rs1057910	100%	100%	
	rs4244285	100%	100%	
CYP2C19	rs4986893	100%	100%	
	rs12248560	100%	100%	
	rs1065852	100%	100%	
CVPDDA	rs5030655	100%	100%	
CIF2D0	rs3892097	100%	100%	
	rs35742686	100%	100%	

	rs16947	100%	100%
	rs28371725	100%	100%
	rs1135840	100%	100%
	rs769258	100%	100%
	rs5030865	100%	100%
	rs5030656	100%	100%
	rs59421388	100%	100%
	rs267608319	100%	100%
SLC01B1	rs4149056	100%	100%

Table 5 Intra-precision and inter-precision for *CYP2D6* Copy Number

Formalo	Variant	Average Copy	Sampla Siza n	Coefficient of Variation		
Sample	variant	Number	Sample Size, ii	Intra-precision	Inter-precision	
221374	Intron 2	2	11	4%	6%	
	Exon 9	1		5%	5%	
222660	Intron 2	2	9	3%	5%	
	Exon 9	2		4%	6%	
222769	Intron 2	3	22	4%	10%	
	Exon 9	2		6%	13%	

Table 6 Genotype concordance for genes CYP2C9, CYP2C19, CYP2D6 and SLCO1B1

Gene	Variant	Genotype	Sample Size Per Genotype [†]	Concordance to Benchmark, % [‡]	Discordant Calls By Nala PGx Core ^{TM§}
CYP2C9	rs1799853	C/C	212	100.0	0
	N = 225	C/T	13		0
		T/T	0		0
	rs1057910	A/A	204	100.0	0
	N = 225	A/C	21		0
		C/C	0		0
CYP2C19	rs4244285	G/G	121	96.9	1
	N = 225	A/G	89		2
		A/A	15		4
	rs4986893	G/G	206	98.7	2
	N = 225	A/G	19		1
		A/A	0		0
	rs12248560	C/C	0	100.0	0
	N = 225	C/T	0		0
		T/T	0		0
CYP2D6	rs1065852	G/G	77	99.6	0
	N = 225	A/G	76		1
		A/A	72		0
	rs5030655	A/A	224	100.0	0
	N = 225	delA/A	1		0
		delA/delA	0		0
	rs3892097	C/C	205	100.0	0
	N = 225	C/T	16		0
		T/T	4		0
	rs35742686	T/T	225	100.0	0
	N = 225	delT/T	0		0
		delT/delT	0		0
	rs16947	G/G	145	96.9	2
	N = 225	A/G	64		4
		A/A	16		1
	rs28371725	C/C	204	100.0	0
	N = 225	C/T	19		0
		T/T	2		0
	rs1135840	C/C	33	97.8	1

	N = 225	C/G	68		1
		G/G	124		3
	rs769258	C/C	220	100.0	0
	N = 225	C/T	5		0
		T/T	0		0
	rs5030865	C/C	222	99.6	0
	N = 225	C/T	3		1
		T/T	0		0
	rs5030656	CTT/CTT	224	100.0	0
	N = 225	delCTT/CTT	1		0
		delCTT/delCTT	0		0
	rs59421388	C/C	224	100.0	0
	N = 225	C/T	1		0
		T/T	0		0
	rs267608319	C/C	225	100.0	0
	N = 225	C/T	0		0
		T/T	0		0
SLCO1B1	rs4149056	T/T	182	97.3	2
	N = 225	C/T	42		4
		C/C	1		0

[†]"Sample Size Per Genotype" reflects the counts of each genotype as produced by the benchmark, and not by Nala PGx CoreTM. [‡]Refer to Table 1 for an outline of the benchmark methods used per variant. [§]Discordant calls refer to instances in which Nala PGx CoreTM did not produce a genotype call concordant with the benchmark.

485

486 Table 7 Genotype concordance for CYP2D6 Intron 2 And Exon 9 Copy Number Variations

Gene	Variant	Copy Number	Sample Size Per Copy Number [†]	Concordance to Benchmark, % [‡]	Discordant Calls By Nala PGx Core ^{TM§}
CYP2D6	Intron 2	0	0	99.6	0
	N = 224	1	12		0
		2	130		0
		>=3	82		1
	Exon 9	0	0	98.7	0
	N = 224	1	24		1
		2	193		2
		>=3	7		0

[†]"Sample Size Per Copy Number" reflects the counts of each copy number call as produced by the benchmark, and not by Nala PGx Core[™] [‡]Refer to Table 1 for an outline of the benchmark methods used per variant. [§]Discordant calls refer to instances in which Nala PGx Core[™] did not produce a copy number call concordant with the benchmark.

487

488 489 Table 8 Diplotype concordance for CYP2C9, CYP2C19 and CYP2D6 between Nala PGx CoreTM, and Agena VeriDose[®] Core and *CYP2D6* CNV Panel

	Concordance, % [†]	Discordant Diplotypes			
Genes		Agena VeriDose® Core and <i>CYP2D6</i> CNV Panel	Nala PGx Core™	Instances	
CYP2C9	100% (n = 213)	NA	NA	NA	
CYP2C19	96.4% (n = 223)	*1/*1	*1/*3	1	
		*1/*2	*1/*1	1	
		*1/*2	*1/*3	1	
		*1/*3	*2/*2	1	
		*2/*2	*1/*1	2	
		*2/*2	*1/*2	2	
CYP2D6	94.7% (n = 209)	*1/*1	*2/*2	1	
		*1/*10	*1/*10, CN >=3	1	
		*1/*41	*39/*41	1	
		*2/*2	*1/*1	1	

	*2/*10	*1/*10	1
	*2/*36, CN >=3	*2/*10, CN >=3	1
	*4/*36	*4/*10	2
	*10/*36	*2/*36	1
	*13 *1/*10	*1/*10, CN >=3	1
	*13 *1/*41, CN = 1	*1/*41	1

[†]The concordance presented in this table excludes samples that have mismatches in diplotype calls arising from technological differences between platforms. Please refer to Supplementary Table 7 for a detailed breakdown of all diplotypes detected.

490 491

Table 9 Observed allele frequencies by ethnicity

			, j	Allele Fre	equencies (1	Per This Study)	Allele F	requencies (I	harmGKB)
Gene	Allele or Variant	Indonesian	Chinese	Malay	Indian	Caucasian	Overall	East Asian	Central/ South Asian	European
CYP2C9	*2	0.000	0.000	0.000	0.060	0.172	0.032	0.002	0.114	0.127
(n = 206)	*3	0.000	0.040	0.039	0.100	0.069	0.044	0.038	0.110	0.076
	*2	0.297	0.274	0.289	0.229	0.138	0.256	0.284	0.270	0.147
CYP2C19 (n = 201)	*3	0.041	0.055	0.066	0.000	0.017	0.042	0.072	0.016	0.002
(1 - 201)	*17	0.054	0.007	0.039	0.229	0.138	0.067	0.021	0.171	0.216
	*2	0.088	0.118	0.167	0.140	0.196	0.136	0.121	0.295	0.277
	*4	0.000	0.035	0.069	0.020	0.161	0.051	0.005	0.091	0.185
	*5	0.029	0.028	0.028	0.080	0.000	0.031	0.049	0.046	0.030
	*6	0.000	0.000	0.000	0.000	0.018	0.003	0.000	0.000	0.011
CYP2D6	*9	0.000	0.000	0.000	0.000	0.018	0.003	0.002	0.003	0.028
(n = 195)	*10	0.338	0.299	0.222	0.160	0.143	0.251	0.436	0.087	0.016
	*14	0.000	0.014	0.000	0.000	0.000	0.005	0.003	ND	0.000
	*29	0.000	0.000	0.000	0.000	0.018	0.003	0.000	0.003	0.001
	*36	0.206	0.250	0.181	0.160	0.054	0.190	0.012	0.000	0.000
	*41	0.044	0.056	0.028	0.040	0.071	0.049	0.023	0.123	0.092
<i>SLCO1B1</i> (n = 203)	rs4149056 [†]	0.125	0.074	0.026	0.040	0.167	0.084	0.125‡	0.050‡	0.159‡

"ND" refers to instances in which no data is available for the given allele on PharmGKB.

¹rst140056 refers to the reduced function variant of *SLCO1B1* that is present in *SLCO1B1*5*, *SLCO1B1*15* and *SLCO1B1*17*. ¹Allele frequency values for rs4149056 have been obtained from gnomAD.

492

493 Table 10 Observed diplotype frequencies by ethnicity

			Diplotype Frequencies (Per This Study) [†]											
Gene	Diplotype	Phenotype [‡]	Indo	nesian	Ch	inese	Μ	alay	In	dian	Cau	casian	Ov	erall
			Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq
CYP2C9	*1/*1	NM	39	1.000	69	0.920	35	0.921	17	0.680	16	0.552	176	0.854
	*1/*2	IM	0	0.000	0	0.000	0	0.000	3	0.120	9	0.310	12	0.058
	*1/*3	IM	0	0.000	6	0.080	3	0.079	5	0.200	3	0.103	17	0.083
	*2/*3	PM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.034	1	0.005
CYP2C19	*1/*1	NM	10	0.270	31	0.425	14	0.368	8	0.333	14	0.483	77	0.383
	*1/*2	IM	19	0.514	28	0.384	14	0.368	5	0.208	7	0.241	73	0.363
	*1/*3	IM	3	0.081	6	0.082	3	0.079	0	0.000	1	0.034	13	0.065
	*1/*17	RM	3	0.081	1	0.014	1	0.026	5	0.208	5	0.172	15	0.075
	*2/*2	PM	1	0.027	5	0.068	3	0.079	1	0.042	0	0.000	10	0.050
	*2/*3	PM	0	0.000	2	0.027	2	0.053	0	0.000	0	0.000	4	0.020
	*2/*17	IM	1	0.027	0	0.000	0	0.000	4	0.167	1	0.034	6	0.030
	*17/*17	UM	0	0.000	0	0.000	1	0.026	1	0.042	1	0.034	3	0.015
CYP2D6	*1/*1	NM	6	0.176	7	0.097	5	0.139	4	0.160	2	0.071	24	0.123
	*1/*2	NM	0	0.000	2	0.028	2	0.056	3	0.120	3	0.107	10	0.051
	*1/*2, CN >=3	UM	0	0.000	0	0.000	0	0.000	1	0.040	1	0.036	2	0.010
	*1/*4	IM	0	0.000	2	0.028	1	0.028	0	0.000	4	0.143	7	0.036
	*1/*5	IM	0	0.000	2	0.028	1	0.028	1	0.040	0	0.000	4	0.021

*1/*6	IM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
*1/*10	NM	4	0.118	3	0.042	2	0.056	2	0.080	2	0.071	13	0.067
*1/*14	NM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
*1/*29	NM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
*1/*36	IM	3	0.088	3	0.042	5	0.139	4	0.160	0	0.000	15	0.077
*1/*41	NM	1	0.029	2	0.028	1	0.028	0	0.000	2	0.071	6	0.031
*1/*41, CN >=3	UM	0	0.000	0	0.000	0	0.000	1	0.040	0	0.000	1	0.005
*2/*2	NM	0	0.000	1	0.014	1	0.028	1	0.040	1	0.036	4	0.021
*2/*4	IM	0	0.000	0	0.000	1	0.028	0	0.000	2	0.071	3	0.015
*2/*5	IM	0	0.000	0	0.000	1	0.028	1	0.040	0	0.000	2	0.010
*2/*10	NM	4	0.118	4	0.056	4	0.111	0	0.000	1	0.036	13	0.067
*2/*14	NM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
*2/*36	IM	2	0.059	4	0.056	2	0.056	0	0.000	1	0.036	9	0.046
*2/*41	NM	0	0.000	4	0.056	0	0.000	0	0.000	1	0.036	5	0.026
*4/*4	PM	0	0.000	1	0.014	1	0.028	0	0.000	1	0.036	3	0.015
*4/*5	PM	0	0.000	0	0.000	0	0.000	1	0.040	0	0.000	1	0.005
*4/*9	IM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
*4/*10	IM	0	0.000	1	0.014	1	0.028	0	0.000	0	0.000	2	0.010
*5/*10	IM	0	0.000	2	0.028	0	0.000	1	0.040	0	0.000	3	0.015
*5/*41	IM	2	0.059	0	0.000	0	0.000	0	0.000	0	0.000	2	0.010
*10/*10	IM	3	0.088	1	0.014	2	0.056	0	0.000	2	0.071	8	0.041
*10/*10, CN >=3	IM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
*10/*36	IM	9	0.265	28	0.389	5	0.139	4	0.160	1	0.036	47	0.241
*10/*41	IM	0	0.000	1	0.014	0	0.000	1	0.040	0	0.000	2	0.010
*36/*41	IM	0	0.000	1	0.014	1	0.028	0	0.000	1	0.036	3	0.015

[†]"Obs" and "Freq" are abbreviations for "Observations" and "Frequency" respectively. [‡]"NM, "IM, "PM" and "UM" are abbreviations for "Normal Metabolizer", "Intermediate Metabolizer", "Poor Metabolizer" and "Ultrarapid Metabolizer" respectively.

494 **Figure Legends**

497 498





20

- 499 Supplementary Figure 1. Observed *CYP2D6* Functional Copy Number Frequencies By Ethnicity. Distribution
- 500 of individuals carrying one, two or three or more copies of the CYP2D6 functional gene among the study cohort
- 501 (n=205), grouped per ethnicity.



502

Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia

A. Main Tables and Figures

Table 1 Genes and variants evaluated

						Gen	otyping Methods U	tilized
Gene	Star Allele	Variant	Nucleotide Changes	Effect On Protein	Allele Clinical Function Status	Nala PGx Core™	Agena VeriDose® Core and <i>CYP2D6</i> CNV Panel	TaqMan® DME Genotyping Assays
CVP2C0	*2	rs1799853	3608C>T	R144C	Decreased	Bi-allelic Assay	VeriDose Core	
CIT2C9	*3	rs1057910	42614A>C	1359L	None	Bi-allelic Assay	VeriDose Core	
	*2	rs4244285	19154G>A	Splicing Defect	None	Bi-allelic Assay	VeriDose Core	
CYP2C19	*3	rs4986893	17948G>A	W212X	None	Bi-allelic Assay	VeriDose Core	
	*17	rs12248560	-806C>T	5' Region	Increased	Bi-allelic Assay	VeriDose Core	
	*2	rs1135840	4181G>C	S486T	Normal	Bi-allelic Assay	VeriDose Core	
	*2	rs16947	2851C>T	R296C	Normal	Bi-allelic Assay	VeriDose Core	
	*3	rs35742686	2550delA	Frameshift	None	Bi-allelic Assay	VeriDose Core	
	*4	rs3892097, rs1065852	1847G>A, 100C>T	Splicing Defect, P34S	None	Bi-allelic Assay	VeriDose Core	
	*5	N/A	N/A	Gene Deletion	None	CNV Assay (Intron 2)	CYP2D6 CNV	
	*6	rs5030655	1708delT	Frameshift	None	Bi-allelic Assay	VeriDose Core	
	*8	rs5030865	1759G>T	G169X	None	Tri-allelic Assay	VeriDose Core	
CVMDA	*9	rs5030656	2616delAAG	K281del	Decreased	Bi-allelic Assay	VeriDose Core	
CIF2D0	*10	rs3892097, rs1065852	1847G>A, 100C>T	Splicing Defect, P34S	Decreased	Bi-allelic Assay	VeriDose Core	
	*14	rs5030865	1759G>A	G169R	Decreased	Tri-allelic Assay	VeriDose Core	
	*21	rs72549352	2580_2581in sC	Frameshift	None	Bi-allelic Assay	VeriDose Core	
	*29	rs59421388	3184G>A	V338M	Decreased	Bi-allelic Assay	VeriDose Core	
	*31	rs267608319	4043G>A	R440H	None	Bi-allelic Assay	NA	AH21B9N
	*35	rs769258	31G>A	V11M	Normal	Bi-allelic Assay	NA	C27102444_F0
	*36	N/A	Recombinati on at Exon 9	CYP2D6- 2D7 Hybrid	None	CNV Assay (Exon 9)	CYP2D6 CNV	
	*41	rs28371725	2989G>A	Splicing Defect	Decreased	Bi-allelic Assay	VeriDose Core	
SLCO1B1	\mathbf{NA}^{\dagger}	rs4149056	g.52422T>C	V174A	Decreased	Bi-allelic Assay	VeriDose Core	

[†]Nala PGx CoreTM detects the variant, rs4149056, which is associated with decreased enzymatic activity and is present in three known *SLCO1B1* haplotypes namely, *SLCO1B1*5*, *SLCO1B1*15* and *SLCO1B1*17*.

			Variant Call Rate, % (n=246)	
Gene	Variant	Nala PGx Core™	Agena VeriDose® Core and <i>CYP2D6</i> CNV Panel	TaqMan® DME Genotyping Assays
CYP2C9	rs1799853	100.0	99.2	NA
	rs1057910	100.0	99.6	NA
CYP2C19	rs4244285	100.0	99.6	NA
	rs4986893	100.0	99.6	NA
	rs12248560	100.0	98.8	NA
CYP2D6	rs1065852	98.4	95.9	NA
	rs5030655	100.0	99.2	NA
	rs3892097	98.8	99.2	NA
	rs35742686	100.0	98.8	NA
	rs16947	100.0	99.6	NA
	rs28371725	100.0	99.2	NA
	rs1135840	100.0	99.6	NA
	rs769258	98.8	NA	100.0
	rs5030865	97.2	99.2	NA
	rs5030656	100.0	99.6	NA
	rs59421388	100.0	99.2	NA
	rs267608319	99.6	NA	100.0
	CNV Assay (Intron 2)	99.6	99.2	NA
	CNV Assay (Exon 9)	99.6	99.2	NA
SLCO1B1	rs4149056	100.0	99.2	NA

Table 2 Observed genotype-level call rates per variant per gene per platform

Table 3 Observed diplotype-level call rates per gene per platform

	Diplotype Call	Diplotype Call Rate, % (n=246)							
Gene	Nala PGx Core™	Agena VeriDose® Core and CYP2D6 CNV Panel							
CYP2C9	100.0	97.2							
CYP2C19	100.0	98.8							
CYP2D6	95.9	90.7							

		Concordar	ace rate, %
		Intra-precision	Inter-precision
Gene	Variant	(47 tests in triplicate)	(120 tests across 4 variables)
CVD2C0	rs1799853	100%	100%
CIF2C9	rs1057910	100%	100%
	rs4244285	100%	100%
СҮР2С19	rs4986893	100%	100%
	rs12248560	100%	100%
	rs1065852	100%	100%
	rs5030655	100%	100%
	rs3892097	100%	100%
	rs35742686	100%	100%
	rs16947	100%	100%
CVDDDC	rs28371725	100%	100%
CIP2D6	rs1135840	100%	100%
	rs769258	100%	100%
	rs5030865	100%	100%
	rs5030656	100%	100%
	rs59421388	100%	100%
	rs267608319	100%	100%
SLCO1B1	rs4149056	100%	100%

Table 4 Intra-precision and inter-precision concordance rates

Table 5 Intra-precision and inter-precision for CYP2D6 Copy Number

Samula	Variant	Average Copy	Somulo Sizo n	Coefficient of Variation		
Sample	v ar fairt	Number	Sample Size, ii	Intra-precision	Inter-precision	
221374	Intron 2	2	11	4%	6%	
	Exon 9	1		5%	5%	
222660	Intron 2	2	9	3%	5%	
	Exon 9	2		4%	6%	
222769	Intron 2	3	22	4%	10%	
	Exon 9	2		6%	13%	

Gene	Variant	Genotype	Sample Size Per Genotype [†]	Concordance to Benchmark, % [‡]	Discordant Calls By Nala PGx Core™ [§]
CYP2C9	rs1799853	C/C	212	100.0	0
	N = 225	C/T	13		0
		T/T	0		0
	rs1057910	A/A	204	100.0	0
	N = 225	A/C	21		0
		C/C	0		0
CYP2C19	rs4244285	G/G	121	96.9	1
	N = 225	A/G	89		2
		A/A	13	09.7	4
	rs4980893	G/G	206	98.7	2
	N = 223	A/G	19		1
	rs12248560		0	100.0	0
	N - 225	С/С	0	100.0	0
	11 - 225	С/Т Т/Т	0		0
CYP2D6	rs1065852	G/G	77	99.6	0
011200	N = 225	A/G	76		1
		A/A	72		0
	rs5030655	A/A	224	100.0	0
	N = 225	delA/A	1		0
		delA/delA	0		0
	rs3892097	C/C	205	100.0	0
	N = 225	C/T	16		0
		T/T	4		0
	rs35742686	T/T	225	100.0	0
	N = 225	delT/T	0		0
		delT/delT	0		0
	rs16947	G/G	145	96.9	2
	N = 225	A/G	64		4
	20251525	A/A	10	100.0	1
	rs283/1/25 N = 225	C/C C/T	19	100.0	0
	11 - 225	C/T T/T	2		0
	rs1135840	C/C	33	97.8	1
	N = 225	C/G	68	2710	1
		G/G	124		3
	rs769258	C/C	220	100.0	0
	N = 225	C/T	5		0
		T/T	0		0
	rs5030865	C/C	222	99.6	0
	N = 225	C/T	3		1
		T/T	0		0
	rs5030656	CTT/CTT	224	100.0	0
	N = 225	delCTT/CTT	1		0
		delCTT/delCTT	0	100.0	0
	rs59421388	C/C	224	100.0	0
	N = 225	C/T T/T	1		0
	rc767609210		225	100.0	0
	N - 225	C/C	0	100.0	0
	11 - 225	T/T	0		0
SICOIRI	rs4149056	T/T	182	97 3	2
SLCOIDI	N = 225	C/T	42	2710	4
		C/C	1		0

Table 6 Genotype concordance for genes CYP2C9, CYP2C19, CYP2D6 and SLCO1B1

[†]"Sample Size Per Genotype" reflects the counts of each genotype as produced by the benchmark, and not by Nala PGx Core[™]. [‡]Refer to Table 1 for an outline of the benchmark methods used per variant. [§]Discordant calls refer to instances in which Nala PGx Core[™] did not produce a genotype call concordant with the benchmark.

Table 7 Genotype concordance for CYP2D6 Intron 2 And Exon 9 Copy Number Variations

Gene	Variant	Copy Number	Sample Size Per Copy Number [↑]	Concordance to Benchmark, %‡	Discordant Calls By Nala PGx Core ^{TM§}
CYP2D6	Intron 2	0	0	99.6	0
	N = 224	1	12		0
		2	130		0
		>=3	82		1
	Exon 9	0	0	98.7	0
	N = 224	1	24		1
		2	193		2
		>=3	7		0

^{**}Sample Size Per Copy Number^{*} reflects the counts of each copy number call as produced by the benchmark, and not by Nala PGx Core[™] [‡]Refer to Table 1 for an outline of the benchmark methods used per variant. [§]Discordant calls refer to instances in which Nala PGx Core[™] did not produce a copy number call concordant with the benchmark.

			Discordant Diplotypes							
Genes	Concordance, % [†]	Agena VeriDose® Core and <i>CYP2D6</i> CNV Panel	Nala PGx Core™	Instances						
CYP2C9	100% (n = 213)	NA	NA	NA						
CYP2C19	96.4% (n = 223)	*1/*1	*1/*3	1						
		*1/*2	*1/*1	1						
		*1/*2	*1/*3	1						
		*1/*3	*2/*2	1						
		*2/*2	*1/*1	2						
		*2/*2	*1/*2	2						
CYP2D6	94.7% (n = 209)	*1/*1	*2/*2	1						
		*1/*10	*1/*10, CN >=3	1						
		*1/*41	*39/*41	1						
		*2/*2	*1/*1	1						
		*2/*10	*1/*10	1						
		*2/*36, CN >=3	*2/*10, CN >=3	1						
		*4/*36	*4/*10	2						
		*10/*36	*2/*36	1						
		*13 *1/*10	*1/*10, CN >=3	1						
		*13 *1/*41, CN = 1	*1/*41	1						

Table 8 Diplotype concordance for *CYP2C9*, *CYP2C19* and *CYP2D6* between Nala PGx CoreTM, and Agena VeriDose[®] Core and *CYP2D6* CNV Panel

[†]The concordance presented in this table excludes samples that have mismatches in diplotype calls arising from technological differences between platforms. Please refer to Supplementary Table 7 for a detailed breakdown of all diplotypes detected.

	Allele or Variant			Allele Frequencies (PharmGKB)						
Gene		Indonesian	Chinese	Malay	Indian	Caucasian	Overall	East Asian	Central/ South Asian	European
<i>CYP2C9</i> (n = 206)	*2	0.000	0.000	0.000	0.060	0.172	0.032	0.002	0.114	0.127
	*3	0.000	0.040	0.039	0.100	0.069	0.044	0.038	0.110	0.076
<i>CYP2C19</i> (n = 201)	*2	0.297	0.274	0.289	0.229	0.138	0.256	0.284	0.270	0.147
	*3	0.041	0.055	0.066	0.000	0.017	0.042	0.072	0.016	0.002
	*17	0.054	0.007	0.039	0.229	0.138	0.067	0.021	0.171	0.216
<i>CYP2D6</i> (n = 195)	*2	0.088	0.118	0.167	0.140	0.196	0.136	0.121	0.295	0.277
	*4	0.000	0.035	0.069	0.020	0.161	0.051	0.005	0.091	0.185
	*5	0.029	0.028	0.028	0.080	0.000	0.031	0.049	0.046	0.030
	*6	0.000	0.000	0.000	0.000	0.018	0.003	0.000	0.000	0.011
	*9	0.000	0.000	0.000	0.000	0.018	0.003	0.002	0.003	0.028
	*10	0.338	0.299	0.222	0.160	0.143	0.251	0.436	0.087	0.016
	*14	0.000	0.014	0.000	0.000	0.000	0.005	0.003	ND	0.000
	*29	0.000	0.000	0.000	0.000	0.018	0.003	0.000	0.003	0.001
	*36	0.206	0.250	0.181	0.160	0.054	0.190	0.012	0.000	0.000
	*41	0.044	0.056	0.028	0.040	0.071	0.049	0.023	0.123	0.092
SLCO1B1 (n = 203)	rs4149056 [†]	0.125	0.074	0.026	0.040	0.167	0.084	0.125‡	0.050‡	0.159‡

Table 9 Observed allele frequencies by ethnicity

"ND" refers to instances in which no data is available for the given allele on PharmGKB.

†rs4149056 refers to the reduced function variant of SLCOIBI that is present in SLCOIBI*5, SLCOIBI*15 and SLCOIBI*17.

[‡]Allele frequency values for rs4149056 have been obtained from gnomAD.

Figure 1. *CYP2D6*36* **Frequency By Ethnicity.** Distribution of individuals carrying one or two copies of the *CYP2D6*36* allele among the study cohort (n=205), grouped per ethnicity



	Diplotype	Phenotype [‡]	Diplotype Frequencies (Per This Study) [†]											
Gene			Indonesian		Chinese		Malay		Indian		Caucasian		Overall	
			Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq
CYP2C9	*1/*1	NM	39	1.000	69	0.920	35	0.921	17	0.680	16	0.552	176	0.854
	*1/*2	IM	0	0.000	0	0.000	0	0.000	3	0.120	9	0.310	12	0.058
	*1/*3	IM	0	0.000	6	0.080	3	0.079	5	0.200	3	0.103	17	0.083
	*2/*3	PM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.034	1	0.005
CYP2C19	*1/*1	NM	10	0.270	31	0.425	14	0.368	8	0.333	14	0.483	77	0.383
	*1/*2	IM	19	0.514	28	0.384	14	0.368	5	0.208	7	0.241	73	0.363
	*1/*3	IM	3	0.081	6	0.082	3	0.079	0	0.000	1	0.034	13	0.065
	*1/*17	RM	3	0.081	1	0.014	1	0.026	5	0.208	5	0.172	15	0.075
	*2/*2	PM	1	0.027	5	0.068	3	0.079	1	0.042	0	0.000	10	0.050
	*2/*3	PM	0	0.000	2	0.027	2	0.053	0	0.000	0	0.000	4	0.020
	*2/*17	IM	1	0.027	0	0.000	0	0.000	4	0.167	1	0.034	6	0.030
	*17/*17	UM	0	0.000	0	0.000	1	0.026	1	0.042	1	0.034	3	0.015
CYP2D6	*1/*1	NM	6	0.176	7	0.097	5	0.139	4	0.160	2	0.071	24	0.123
	*1/*2	NM	0	0.000	2	0.028	2	0.056	3	0.120	3	0.107	10	0.051
	*1/*2, CN >=3	UM	0	0.000	0	0.000	0	0.000	1	0.040	1	0.036	2	0.010
	*1/*4	IM	0	0.000	2	0.028	1	0.028	0	0.000	4	0.143	7	0.036
	*1/*5	IM	0	0.000	2	0.028	1	0.028	1	0.040	0	0.000	4	0.021
	*1/*6	IM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
	*1/*10	NM	4	0.118	3	0.042	2	0.056	2	0.080	2	0.071	13	0.067
	*1/*14	NM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
	*1/*29	NM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
	*1/*36	IM	3	0.088	3	0.042	5	0.139	4	0.160	0	0.000	15	0.077
	*1/*41	NM	1	0.029	2	0.028	1	0.028	0	0.000	2	0.071	6	0.031
	*1/*41, CN >=3	UM	0	0.000	0	0.000	0	0.000	1	0.040	0	0.000	1	0.005
	*2/*2	NM	0	0.000	1	0.014	1	0.028	1	0.040	1	0.036	4	0.021
	*2/*4	IM	0	0.000	0	0.000	1	0.028	0	0.000	2	0.071	3	0.015
	*2/*5	IM	0	0.000	0	0.000	1	0.028	1	0.040	0	0.000	2	0.010
	*2/*10	NM	4	0.118	4	0.056	4	0.111	0	0.000	1	0.036	13	0.067
	*2/*14	NM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
	*2/*36	IM	2	0.059	4	0.056	2	0.056	0	0.000	1	0.036	9	0.046
	*2/*41	NM	0	0.000	4	0.056	0	0.000	0	0.000	1	0.036	5	0.026
	*4/*4	PM	0	0.000	1	0.014	1	0.028	0	0.000	1	0.036	3	0.015
	*4/*5	PM	0	0.000	0	0.000	0	0.000	1	0.040	0	0.000	1	0.005
	*4/*9	IM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
	*4/*10	IM	0	0.000	1	0.014	1	0.028	0	0.000	0	0.000	2	0.010
	*5/*10	IM	0	0.000	2	0.028	0	0.000	1	0.040	0	0.000	3	0.015
	*5/*41	IM	2	0.059	0	0.000	0	0.000	0	0.000	0	0.000	2	0.010
	*10/*10	IM	3	0.088	1	0.014	2	0.056	0	0.000	2	0.071	8	0.041
	*10/*10, CN >=3	IM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
	*10/*36	IM	9	0.265	28	0.389	5	0.139	4	0.160	1	0.036	47	0.241
	*10/*41	IM	0	0.000	1	0.014	0	0.000	1	0.040	0	0.000	2	0.010
	*36/*41	IM	0	0.000	1	0.014	1	0.028	0	0.000	1	0.036	3	0.015

Table 10 Observed diplotype frequencies by ethnicity

[†]"Obs" and "Freq are abbreviations for "Observations" and "Frequency" respectively. [‡]"NM, "IM, "PM" and "UM" are abbreviations for "Normal Metabolizer", "Intermediate Metabolizer", "Poor Metabolizer" and "Ultrarapid Metabolizer" respectively.

B. Supplementary Information

Supplementary Table 1. Observed Genotype-Level Call Rates Per Variant Per Gene Per Platform, With Counts Of Successful And No Calls

Supplementary Table 2. Observed Diplotype-Level Call Rates Per Gene Per Platform, With Counts Of Successful And No Calls

Supplementary Table 3. Precision Analysis Of Nala PGx Coretm

Supplementary Table 4. Observed allele frequencies by ethnicity

Supplementary Table 5. CYP2D6 Intron 2 And Exon 9 Observations And Frequencies By Ethnicity

Supplementary Table 6. CYP2D6*36 Observations And Frequencies By Ethnicity

Supplementary Table 7. Diplotype Calls Observed Across All Samples Tested On Agena Veridose® Core And *CYP2D6* CNV Panel And Nala PGx Core[™]

Supplementary Table 8. Raw And Reported Diplotype Concordance Values For Samples Tested On Agena Veridose® Core And CYP2D6 CNV Panel And Nala PGx CoreTM

Supplementary Tables 9.1 to 9.18. Raw genotype calls for rs1799853, rs1057910, rs4244285, rs4986893, rs12248560, rs1065852, rs5030655, rs3892097, rs35742686, rs16947, rs28371725, rs1135840, rs769258, rs5030865, rs5030656, rs59421388 and rs267608319, on Nala PGx CoreTM and the corresponding benchmark methods, Agena VeriDose[®] Core and *CYP2D6* CNV Panel or TaqMan[®] DME Genotyping Assays

Supplementary Table 9.19. Raw variant calls for *CYP2D6* Intron 2 and Exon 9 on Agena VeriDose® Core and *CYP2D6* CNV Panel and Nala PGx Core[™]

Supplementary Figure 1. Observed *CYP2D6* **Functional Copy Number Frequencies By Ethnicity.** Distribution of individuals carrying one, two or three or more copies of the *CYP2D6* functional gene among the study cohort (n=205), grouped per ethnicity.